Anti-tumor effects of a novel chimeric peptide on S180 and H22 xenografts bearing nude mice

Peptides

Volumn 31, Issue 5, 2010, Pages 850-864

  Wu, Dongdong ^a   Gao, Yanfeng ^a   Chen, Lixiang ^a   Qi, Yuanming ^a   Kang, Qiaozhen ^a   Wang, Haili ^a   Zhu, Linyu ^a   Ye, Yong ^a   Zhai, Mingxia ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Angiogenesis; Peptide; Tie 2; Tumor; VEGFR 2

Indexed keywords

ALANYLTHREONYLTRYPTOPHANYLLEUCYLPROLYLPROLYLARGINYLALANYLALANYLASPARAGINYLLEUCYLLEUCYLMETHIONYLALANYLALANYLSERINE; ALANYLTHREONYLTRYPTOPHYLLEUCYLPROLYLPROLYLARGININE; ANTINEOPLASTIC AGENT; ASPARAGINYLLEUCYLLEUCYLMETHIONYLALANYLALANYLSERINE; CHIMERIC PROTEIN; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; LIVER CELL CARCINOMA; LOW DRUG DOSE; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; TISSUE NECROSIS; TREATMENT DURATION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD34; BODY WEIGHT; CELL LINE, TUMOR; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; MUS MUSCULUS;

EID: 77951257822     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2010.01.007     Document Type: Article

References (51)

1. Ainars L., Edvards L., Mikhail B., Anatoly S., Maria G.M., Gottfried O. Random coil conformation of a Gly/Ala-rich insert in IκBα excludes structural stabilization as the mechanism for protection against proteasomal degradation. FEBS Lett 1998, 440:365-369.
2. Athanassiades A., Lala P.K. Role of placenta growth factor (PIGF) in human extravillous trophoblast proliferation, migration and invasiveness. Placenta 1998, 19:465-473.
3. Binétruy-Tournaire R., Demangel C., Malavaud B., Vassy R., Rouyre S., Kraemer M., et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J 2000, 19:1525-1533.
4. Boudreau N., Myers C. Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment. Breast Cancer Res 2003, 5:140-146.
5. Conway M.E., Collen D., Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001, 49:507-521.
6. Dandu R., Zulli A.L., Bacon E.R., Underiner T., Robinson C., Chang H., et al. Design and synthesis of dihydroindazolo [5,4-a] pyrrolo [3,4-c] carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases. Bioorg Med Chem Lett 2008, 18:1916-1921.
7. Di Benedetto M., Starzec A., Vassy R., Perret G.Y., Crépin M. Distinct heparin binding sites on VEGF165 and its receptors revealed by their interaction with a non sulfated glycoaminoglycan (NaPaC). Biochim Biophys Acta 2008, 1780:723-732.
8. Dings R.P., Van-Laar E.S., Webber J., Zhang Y., Griffin R.J., Waters S.J., et al. Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Lett 2008, 265:270-280.
9. Dings R.P., Williams B.W., Song C.W., Griffioen A.W., Mayo K.H., Griffin R.J., et al. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cell. Int J Cancer 2005, 115:312-319.
10. Dings R.P., Yokoyama Y., Ramakrishnan S., Griffioen A.W., Mayo K.H. The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res 2003, 63:382-385.
11. Economidou F., Antoniou K.M., Tzanakis N., Sfiridaki K., Siafakas N.M., Schiza S.E. Angiogenic molecule Tie-2 and VEGF in the pathogenesis of pleural effusions. Respir Med 2008, 102:774-779.
12. El-Refael M.F., Sarkar N.H. Snake venom inhibits the growth of mouse mammary tumor cells in vitro and in vivo. Toxicon 2009, 54:33-41.
13. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
14. Gale N.W., Thurston G., Hackett S.F., Renard R., Wang Q., McClain J., et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002, 3:411-423.
15. George S.K., Rajesh R., Kumar S.S., Sulekha B., Balaram P. A polyherbal ayurvedic drug-Indukantha Ghritha as an adjuvant to cancer chemotherapy via immunomodulation. Immunobiology 2008, 213:641-649.
16. Hiratsuka S., Maru Y., Okada A., Seiki M., Noda T., Shibuya M. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 2001, 61:1207-1213.
17. Hodous B.L., Geuns-Meyer S.D., Hughes P.E., Albrecht B.K., Bellon S., Caenepeel S., et al. Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors. Bioorg Med Chem Lett 2007, 17:2886-2889.
18. Ito Y., Betsuyaku T., Nagai K., Nasuhara Y., Nishimura M. Expression of pulmonary VEGF family declines with age and is further down-regulated in lipopolysaccharide (LPS)-induced lung injury. Exp Gerontol 2005, 40:315-323.
19. Kaji T., Yamamoto C., Oh-i M., Fujiwara Y., Yamazaki Y., Morita T., et al. The vascular endothelial growth factor VEGF165 induces perlecan synthesis via VEGF receptor-2 in cultured human brain microvascular endothelial cells. Biochim Biophys Acta 2006, 1760:1465-1474.
20. Kosugi M., Miyajima A., Kikuchi E., Kosaka T., Horiguchi Y., Murai M., et al. Angiotensin II type 1 receptor antagonist enhances cis-dichlorodiammineplatinum-induced cytotoxicity in mouse xenograft model of bladder cancer. Urology 2009, 73:655-660.
21. Maglione D., Battisti M., Tucci M. Recombinant production of PIGF-1 and its activity in animal models. Farmaco 2000, 55:165-167.
22. Mamoru F., Izumi H., Shohei Y., Moritoshi I., Masataka M. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 2002, 294:441-447.
23. Paris D., Quadros A., Patel N., DelleDonne A., Humphrey J., Mullan M. Inhibition of angiogenesis and tumor growth by β and γ-secretase inhibitor. Eur J Pharmacol 2005, 514:1-15.
24. Peng C.L., Lai P.S., Lin F.H., Yueh-Hsiu Wu S., Shieh M.J. Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles. Biomaterials 2009, 30:3614-3625.
25. Perret G.Y., Starzec A., Hauet N., Vergote J., Le Pecheur M., Vassy R., et al. In vitro evaluation and biodistribution of a 99mTc-labelled anti-VEGF peptide targeting neuropilin-1. Nucl Med Biol 2004, 31:575-581.
26. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R., Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005, 16:159-178.
27. Qiu L., Yoshida K., Amorima B.R., Okamura H., Haneji T. Calyculin A stimulates the expression of TNF-α mRNA via phosphorylation of Akt in mouse osteoblastic MC3T3-E1 cells. Mol Cell Endocrinol 2007, 271:38-44.
28. Rajah T.T., Grammas P. VEGF and VEGF receptor levels in retinal and brain-derived endothelial cells. Biochem Biophys Res Commun 2002, 293:710-713.
29. Sarraf-Yazdi S., Mi J., Moeller B.J., Niu X., White R.R., Kontos C.D., et al. Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer. J Surg Res 2008, 146:16-23.
30. Sengupta S., Gherardi E., Sellers L.A., Wood J.M., Sasisekharan R., Fan T.P. Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2003, 23:69-75.
31. Seval Y., Sati L., Celik-Ozenci C., Taskin O., Demir R. The distribution of angiopoietin-1, angiopoietin-2 and their receptors tie-1 and tie-2 in the very early human placenta. Placenta 2008, 29:809-815.
32. Shimoda S., Ichihara H., Matsumoto Y., Ueoka R. Chemotherapy with hybrid liposomes for human breast tumors along with apoptosis in vivo. Int J Pharm 2009, 372:162-168.
33. Slimani H., Guenin E., Briane D., Coudert R., Charnaux N., Starzec A., et al. Lipopeptide-based liposomes for DNA delivery into cells expressing neuropilin-1. J Drug Target 2006, 14:694-706.
34. Sporn M.B., Suh N. Chemoprevention of cancer. Carcinogenesis 2000, 21:525-530.
35. Starzec A., Ladam P., Vassy R., Badache S., Bouchemal N., Navaza A., et al. Structure-function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF165 binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex. Peptides 2007, 28:2397-2402.
36. Starzec A., Vassy R., Martin A., Lecouvey M., Di Benedetto M., Crépin M., et al. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. Life Sci 2006, 79:2370-2381.
37. Stoeck A., Schlich S., Issa Y., Gschwend V., Wenger T., Herr I., et al. L1 on ovarian carcinoma cells is a binding partner for neuropilin-1 on mesothelial cells. Cancer Lett 2006, 239:212-226.
38. Takekiyo T., Shimizu A., Kato M., Taniguchi Y. Pressure-tuning FT-IR spectroscopic study on the helix-coil transition of Ala-rich oligopeptide in aqueous solution. Biochim Biophys Acta 2005, 1750:1-4.
39. Thurston G., Rudge J.S., Ioffe E., Zhou H., Ross L., Croll S.D., et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000, 6:460-463.
40. Tirand L., Frochot C., Vanderesse R., Thomas N., Trinquet E., Pinel S., et al. A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells. J Control Release 2006, 111:153-164.
41. Tournaire R., Simon M.P., Ie Noble F., Eichmann A., England P., Pouysségur J. A short synthetic peptide inhibits signal transduction, migration and angiogenesis mediated by Tie2 receptor. EMBO Rep 2004, 5:262-267.
42. Underiner T.L., Ruggeri B., Aimone L., Albom M., Angeles T., Chang H., et al. TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-a] pyrrolo[3,4-c]carbazole analogs. Bioorg Med Chem Lett 2008, 18:2368-2372.
43. Warner-Schmidt J.L., Duman R.S. VEGF as a potential target for therapeutic intervention in depression. Curr Opin Pharmacol 2008, 8:14-19.
44. Wilgus T.A., Ferreira A.M., Oberyszyn T.M., Bergdall V.K., Dipietro L.A. Regulation of scar formation by vascular endothelial growth factor. Lab Invest 2008, 88:579-590.
45. Xu H.S., Wu Y.W., Xu S.F., Sun H.X., Chen F.Y., Yao L. Antitumor and immunomodulatory activity of polysaccharides from the roots of Actinidia eriantha. J Ethnopharmacol 2009, 125:310-317.
46. Xu Y.F., Zhu L.P., Hu B., Rong Z.G., Zhu H.W., Xu J.M., et al. A quantitative method for measuring the antitumor potency of recombinant human endostatin in vivo. Eur J Pharmacol 2007, 564:1-6.
47. Yamaguchi N., Chae B.S., Zhang L., Kiick K.L., Furst E.M. Rheological characterization of polysaccharide-poly (ethylene glycol) star copolymer hydrogels. Biomacromolecules 2005, 6:1931-1940.
48. Yamaguchi N., Kiick K.L. Polysaccharide-poly(ethyleneglycol) star copolymer as a scaffold for the production of bioactive hydrogels. Biomacromolecules 2005, 6:1921-1930.
49. Yao Z., Lu R., Jia J., Zhao P.P., Yang J., Zheng M.N., et al. The effect of tripeptide tyroserleutide (YSL) on animal models of hepatocarcinoma. Peptides 2006, 27:1167-1172.
50. Yuan F., Qin X., Zhou D., Xiang Q.Y., Wang M.T., Zhang Z.R., et al. In vitro cytotoxicity, in vivo biodistribution and antitumor activity of HPMA copolymer-5-fluorouracil conjugates. Eur J Pharm Biopharm 2008, 70:770-776.
51. Zhu L.P., Xing J., Wang Q.X., Kou L., Li C., Hu B., et al. Therapeutic efficacy of recombinant human endostatin combined with chemotherapeutics in mice-transplanted tumors. Eur J Pharmacol 2009, 617:23-27.